구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing.
기전. Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
c-Met
Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression
US
Approved
emrelis · telisotuzumab vedotin · Emrelis · ABBV-399 · Teliso-V · telisotuzumab-vedotin-tllv
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
MMAE (microtubule inhibitor)
Cleavable vc linker, vedotin chemistry
Humanized IgG1 against c-Met (telisotuzumab)
Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs.
구조화 데이터
Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs.
c-Met down-regulation, MMAE efflux, and histologic transformation.
MMAE (microtubule inhibitor)
Cleavable vc linker, vedotin chemistry
c-Met · VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping.
Peripheral neuropathy, edema, ocular surface monitoring as with vedotin ADCs
Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing.
EGFR wild-type non-squamous NSCLC after prior systemic therapy, high c-Met (≥50% of tumor cells 3+)
2L+
IV
1.9 mg/kg q2w
ORR 35% in LUMINOSITY high c-Met cohort
Peripheral neuropathy, edema, ocular surface monitoring as with vedotin ADCs
Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing.
Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion.
Microtubule inhibition → mitotic arrest and apoptosis.
VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping.
c-Met down-regulation, MMAE efflux, and histologic transformation.
구조화 데이터
Human
ADC in the range of days; free MMAE shorter
ORR and DOR by BICR
구조화 데이터
차트 로드 중…
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (c-Met-high nsq NSCLC)
APPROVAL · 2025년 5월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing.
기전. Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
c-Met
Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression
US
Approved
emrelis · telisotuzumab vedotin · Emrelis · ABBV-399 · Teliso-V · telisotuzumab-vedotin-tllv
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
MMAE (microtubule inhibitor)
Cleavable vc linker, vedotin chemistry
Humanized IgG1 against c-Met (telisotuzumab)
Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs.
구조화 데이터
Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs.
c-Met down-regulation, MMAE efflux, and histologic transformation.
MMAE (microtubule inhibitor)
Cleavable vc linker, vedotin chemistry
c-Met · VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping.
Peripheral neuropathy, edema, ocular surface monitoring as with vedotin ADCs
Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing.
EGFR wild-type non-squamous NSCLC after prior systemic therapy, high c-Met (≥50% of tumor cells 3+)
2L+
IV
1.9 mg/kg q2w
ORR 35% in LUMINOSITY high c-Met cohort
Peripheral neuropathy, edema, ocular surface monitoring as with vedotin ADCs
Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing.
Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion.
Microtubule inhibition → mitotic arrest and apoptosis.
VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping.
c-Met down-regulation, MMAE efflux, and histologic transformation.
구조화 데이터
Human
ADC in the range of days; free MMAE shorter
ORR and DOR by BICR
구조화 데이터
차트 로드 중…
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval (c-Met-high nsq NSCLC)
APPROVAL · 2025년 5월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.